Compounds > 1,3-dipropyl-8-cyclopentylxanthine

1,3-dipropyl-8-cyclopentylxanthine and 3,4-dihydroxyphenylacetic acid

1,3-dipropyl-8-cyclopentylxanthine has been researched along with 3,4-dihydroxyphenylacetic acid in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J1
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J1
Beilstein, M; Castagnoli, K; Castagnoli, N; Chen, JF; Petzer, JP; Schwarzschild, MA; Sonsalla, PK; Staal, R; Xu, K; Xu, YH1
Dziubina, A; GoĊ‚embiowska, K1
Chiu, TH; Hsu, CW; Wang, CS1

Other Studies

5 other study(ies) available for 1,3-dipropyl-8-cyclopentylxanthine and 3,4-dihydroxyphenylacetic acid

ArticleYear
Chemical genetics reveals a complex functional ground state of neural stem cells.
    Nature chemical biology, 2007, Volume: 3, Issue:5

    Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells

2007
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
    Nature chemical biology, 2009, Volume: 5, Issue:10

    Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection

2009
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2001, May-15, Volume: 21, Issue:10

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caffeine; Catechols; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Immunity, Innate; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neuroprotective Agents; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Purines; Pyrimidines; Receptor, Adenosine A2A; Receptors, Purinergic P1; Theobromine; Triazoles; Xanthines

2001
Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats.
    Neuropharmacology, 2004, Volume: 47, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Area Under Curve; Brain Chemistry; Chromatography, High Pressure Liquid; Corpus Striatum; Denervation; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Extracellular Space; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Malonates; Methyltyrosines; Rats; Rats, Wistar; Receptor, Adenosine A2A; Reserpine; Serotonin; Substantia Nigra; Time Factors; Triazines; Triazoles; Xanthines

2004
Caffeine and a selective adenosine A2A receptor antagonist induce sensitization and cross-sensitization behavior associated with increased striatal dopamine in mice.
    Journal of biomedical science, 2010, Jan-15, Volume: 17

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Caffeine; Dopamine; Homovanillic Acid; Male; Mice; Mice, Inbred BALB C; Neostriatum; Neuroprotective Agents; Phosphorylation; Pyrimidines; Serine; Triazoles; Tyrosine 3-Monooxygenase; Xanthines

2010